Clinical trial NCT06288542: Preoperative Dextrose Infusion and Postoperative Nausea and Vomiting
Official title: The Relationship of Preoperative Intravenous Dextrose Infusion to Postoperative Nausea and Vomiting in Gynecological Laparoscopic and Hysteroscopic Surgeries: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Effect of Dextrose on Postoperative Nausea and Vomiting
Keywords: dextrose infusion
postoperative nausea and vomiting
gynecological laparoscope and hysteroscope
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-03-01
Enrollment: 111
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This research aims to investigate the efficacy of preoperative intravenous infusion of dextrose 5% during fasting in lowering the incidence and severity of post-operative nausea and vomiting related to laparoscopic gynaecologic procedures

Detailed description: A history of PONV risk factors will be recorded. After consenting, patients will be assigned using a computerized randomization function to Ringer solution (group R) or 5% dextrose (group D) or control group (group C). Group D will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia. Group R will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia. Group C will receive no fluids. The anesthesia providers, surgeons, perioperative nurses, postanesthesia care unit (PACU) nurses and investigators will be blinded to group assignment throughout.

As for pre-medication, all patients will receive IV midazolam (0.02 mg/kg). Anesthesia will be induced with propofol (1.5-2 mg/kg), fentanyl (1-2 μg/kg) and atracurium(o.5mg/kg) to facilitate endotracheal intubation. The lungs will be mechanically ventilated and anesthesia will be maintained with isoflurane in O2/air. Intraoperative IV maintenance fluid will be standardized at 3 mL/kg/h with additional IV crystalloid given as needed at the discretion of the anesthesia provider if arterial blood pressure decreased \&gt;20% from baseline. For postoperative pain relief, paracetamol 1 g will be given I.V. during surgery in all patients and continued orally after operation (1g every 6 h). In addition, all patients will be ambulated within 6 h after completion of surgery. Standardized antiemetic and analgesic rescue medications will be available. Patients will receive no rescue antiemetic medication when the VRS score is 0 to 2; 1 dose of rescue medication when the VRS score is 3 to 6; and ≥2 doses for nausea score of 7 to 10, to reduce the nausea score to 0 to 2.

Eligibility criteria: Inclusion Criteria:

* Adult female patients scheduled for elective laparoscopic gynecological/hysteroscopic procedures will be considered for inclusion
* ASA physical status I and ll.

Exclusion Criteria:

* patients with a previous history of PONV.
* Patients with motion sickness, coagulopathy, diabetes mellitus, or severe hypertension
* patients with cardiac, renal or hepatic dysfunction.
* patients receiving an antiemetic agent within 24 h before surgery or cases where complications occurs during the surgery
* patients who have abnormal blood glucose on the night before surgery
* patients who are unable to understand and use the verbal rating scale (VRS);Growth developmental, and motor-mental retardation.

Primary outcomes:
measure: frequency of post-opertive nausea and vomiting in 24 hour
timeFrame: FROM ENROLLMENT TO 24 HOURS AFTER SURGERY
Secondary outcomes:
measure: TOTAL AMOUNT OF ANTIEMETIC REQUIRED
timeFrame: From end of surgery to 24 hours postoperative
Other outcomes:
Locations:
Study officials:
References: